The semisynthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) has several biological activities, including the induction of apoptosis in many cancer cell lines. To identify potential protein targets, immobilized biotinylated CDDO was used to screen the proteome of a human lymphoma cell line (U937) sensitive to CDDO-induced apoptosis. Tubulin was identified as one of several putative targets of CDDO. CDDO was shown to selectively bind to tubulin, with a dissociation constant of ϳ7 M, and to disrupt microtubules both in vivo and in vitro. CDDO inhibits tubulin polymerization in vitro, possibly through interactions with a hydrophobic site on ␤-tubulin. The CDDO-tubulin interaction may also involve a reversible 1,4-addition with a protein sulfhydryl group. Unlike other known spindle poisons, CDDO does not result in a temporal increase in the mitotic index. Rather, CDDO seems to initiate apoptosis early in M phase.
Microtubules have long been recognized as the target for a large and chemically diverse group of chemotherapeutic agents (Cragg and Newman, 2004) . Microtubules are dynamic protein polymers comprised of 12 to 13 protofilaments arranged to form a pipe-like structure (Downing, 2000) . Protofilaments consist of ␣-and ␤-tubulin heterodimers combined in a head-to-tail arrangement. The GTP-dependent polymerization of microtubules occurs by a nucleation-elongation mechanism, in which a short microtubule nucleus is formed and then elongated by the noncovalent, reversible addition of tubulin heterodimers. Once formed, microtubules exist in a dynamic equilibrium, a feature that is crucial to their cellular function (Jordan, 2002) . Because microtubules are intimately involved in the formation of the mitotic spindle, agents that interfere with microtubule dynamics (often called spindle poisons) typically inhibit cell cycle progression through mitosis and ultimately initiate apoptosis . Spindle poisons are generally categorized into separate classes depending on their binding site; there are classes for agents that bind to tubulin at the colchicine site (e.g., colchicine, nocodazole), the vinca alkaloid site (e.g., vinblastine), the peptide site (e.g., cryptophycin 1), the paclitaxel (Taxol) site (e.g., epothilones), the tubulin sulfhydryl groups (e.g., stypoldione), or other/uncharacterized binding sites (e.g., lupeol) (Luduena and Roach, 1991; Downing, 2000) .
The semisynthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) was derived from oleanolic acid ( Fig. 1 ) through iterative structure-activity relationship studies, employing an inducible nitric-oxide synthase (iNOS) assay (Honda et al. 1997 (Honda et al. , 1998 (Honda et al. , 2000a (Honda et al. ,b, 2002 . CDDO at nanomolar concentrations suppresses the de novo synthesis of the inflammatory enzymes iNOS and cyclooxygenase-2 in activated macrophages (Suh et al., 1999) . Additional studies with CDDO have revealed potent differentiating, antiproliferative, and apoptotic activity, suggesting the possibility of multiple targets (Wang et al., 2000) . Micromolar concentrations of CDDO (ca. 1-10 M) have been observed to induce apoptosis in several cancer cell lines, including myeloid (Ito et al., 2000; Stadheim et al., 2002) and lymphocytic leukemia cells (Pedersen et al., 2002; Inoue et al., 2004) , osteosarcoma cells (Ito et al., 2001) , nonsmall cell lung carcinoma cells , breast cancer cells (Lapillonne et al., 2003) , and skin cancer cells (Hail et al., 2004) . In general, the process of apoptosis can be divided into three phases (Kroemer et al., 1995) : the induction phase (cells receive a stimulus that initiates programmed cell death), the effector phase (proteases and nucleases become systematically activated), and the degradation phase (numerous vital structures and functions are destroyed, ultimately leading to cytolysis). Several investigations have offered insights into the effector and degradation phases of CDDO-induced apoptosis (Ito et al., 2000 (Ito et al., , 2001 Pedersen et al., 2002; Stadheim et al., 2002; Lapillonne et al., 2003; Hail et al., 2004) . However, a target protein of CDDO that could initiate the induction phase had not been previously identified.
In this report, we describe the identification and validation of ␤-tubulin as one target of CDDO; the inhibition of microtubule dynamics may contribute to the initiation of CDDOinduced programmed cell death. CDDO has been shown to exert its effects in vivo using immunofluorescent microscopy of osteosarcoma cells. In vitro, CDDO exhibits a dose-dependent effect on tubulin polymerization, more potent binding to microtubules than to soluble tubulin, and competitive binding with bis-ANS, a known microtubule poison that interacts with a hydrophobic site on tubulin.
Materials and Methods
Column Chromatography and Protein Identification. Chromatography resin was prepared by combining 0.3 mg of biotinylated CDDO (Honda et al., 2004 ) with 1 ml of streptavidin gel slurry (Pierce Biotechnology, Rockford, IL) and incubating for 1 h at 4°C. The resin was transferred to a chromatography column (13 mm i.d.), and unbound biotinylated CDDO was removed by washing three times with 1 ml of column buffer A [100 mM Tris, pH 7.5 and 1% Triton X-100 (all common reagents were obtained from SigmaAldrich, St. Louis, MO)]. Human lymphoma (U937) cells (Sundstrom and Nilsson, 1976) were lysed by resuspending 2.6 g of cells in 5 ml of lysis buffer [Cellytic M reagent (Sigma-Aldrich) supplemented with 1% Triton X-100, 100 units of DNase, 100 units of RNase, and 1 tablet of protease inhibitor cocktail (Roche, Indianapolis, IN)] and incubating for 1 h at 4°C. Differential centrifugation clarified the lysate, which was then passed through the chromatography column twice (all steps were performed at 4°C). The column was then washed with 10-column volumes of buffer A, 40-column volumes of 100 mM Tris, pH 7.5, and 10-column volumes of buffer A. Elution was accomplished with 6 ϫ 1-ml aliquots of a 1.6 mg/ml CDDO solution in buffer A. Purified proteins were precipitated with 10% trichloroacetic acid, electrophoresed (8-16% SDS-PAGE; Bio-Rad, Hercules, CA), and visualized using a SilverQuest silver staining kit (Invitrogen, Carlsbad, CA). Protein bands were excised from the gel and analyzed by liquid chromatography-tandem mass spectrometry as described previously (Ory et al., 2003) .
Secondary Screen. [ 14 C]CDDO (4.5 M, 52.5 mCi/mmol; 0.21 Ci/l, labeled in the cyano moiety, synthesized through the National Cancer Institute-Rapid Access to Intervention Development program) was incubated with either 5 M tubulin (Cytoskeleton, Denver, CO), 5 M bovine serum albumin (BSA), or water in general tubulin buffer (80 mM PIPES, pH 6.9, 2 mM MgCl 2 , and 0.5 mM EGTA) for 30 min at 25°C. Unbound [ 14 C]CDDO was removed by gel filtration (MicroSpin G50; GE Healthcare, Little Chalfont, Buckinghamshire, UK). The amount of protein-bound radioactivity was quantified with 20 l of each eluate in scintillation cocktail.
Indirect Immunofluorescent Microscopy. Human U2OS cells, treated with DMSO, CDDO (5-50 M), or nocodazole (10 M), were processed for immunofluorescence as described elsewhere (Ganem and Compton, 2004) . Primary antibodies (tubulin antibody DM1␣; Sigma-Aldrich) were detected using species-specific fluorescein-conjugated secondary antibodies (Vector Labs, Burlingame, CA), and DNA was detected with 0.2 g/ml 4Ј-6-diamidine-2-phenyl indole (Sigma-Aldrich). Fluorescent images were captured with a Hamamatsu Orca II cooled charge-coupled device camera mounted on a Zeiss Axioplan 2 microscope (Carl Zeiss Inc., Thornwood, NY). A series of 0.5-m optical sections were collected in the z plane for each channel (4Ј-6-diamidine-2-phenyl indole and fluorescein) and deconvolved using Openlab software (Improvision Inc., Lexington, MA) to eliminate extraneous fluorescence background.
Mitotic Index. Osteosarcoma cells were treated with either 10 M nocodazole, 5 M CDDO, or DMSO alone, and mitotic indices were observed by phase contrast microscopy using a Nikon TE2000-E inverted light microscope equipped with a 40ϫ objective (Nikon, Melville, NY). The mitotic index is reported as the percentage of mitotic cells per total cell number of cells. Scintillation Proximity Assays. The dissociation constant was determined using 100-l assays containing general tubulin buffer, 0.2 M biotinylated tubulin (Cytoskeleton), and variable [ 14 C]CDDO concentrations. After a 15-min incubation at 37°C, 80 g of streptavidin-coated yttrium beads (GE Healthcare) were added, and the mixture was further incubated for 50 min at 25°C. Tubes were then molpharm.aspetjournals.org centrifuged (16,100g, 2 min, 25°C) and quantified using a Tri-Carb scintillation counter (PerkinElmer Life and Analytical Sciences, Boston, MA). The dissociation constant was determined from nonlinear regression curve fitting using Prism software (ver. 4; GraphPad Software Inc., San Diego, CA).
Competitive binding studies were performed essentially as described above with the exception of preincubating the biotinylated tubulin with the indicated amount of competing ligand (1 h, 37°C) followed by the addition of 10 M [ 14 C]CDDO. Competitive versus noncompetitive inhibition was graphically determined using variable concentrations of [
14 C]CDDO with fixed concentrations of bis-ANS.
Tubulin Polymerization and Depolymerization Assays. Polymerization was monitored at 340 nm in a Shimadzu spectrophotometer using the Tubulin Polymerization Assay kit (Cytoskeleton) with a slightly modified protocol. In brief, 50 l of tubulin (80 M) was incubated in a microcentrifuge tube for 5 min on ice with the indicated concentration of CDDO, colchicine, vinblastine, or bis-ANS (each added in a 5-l volume) and then was diluted to 40 M with ice-cold general tubulin buffer. One-hundred-five microliters of the assay solution was then transferred to a prewarmed cuvette to begin the assay. Temperature was maintained at 37°C throughout the duration of polymerization, and the OD 340 was measured every 4 min. A plot of percent tubulin polymerized (OD 340 at 60 min) versus the log of CDDO concentration was used to determine the IC 50 value. Microtubule depolymerization was evaluated by the addition of the indicated concentrations of CDDO at 60 min and following the OD 340 thereafter.
Interactions of CDDO with Microtubules and Soluble Tubulin. Tubulin (40 M) was polymerized for 1 h at 37°C in the presence of 0, 10, 33, or 55 M [
14 C]CDDO. Microtubules were collected by centrifugation (16,100g, 10 min, 25°C) and washed twice with 50 l of 37°C general tubulin buffer, whereas soluble tubulin was transferred to a prechilled (4°C) MicroSpin G50 column to remove unbound [
14 C]CDDO. The microtubule pellet was resuspended in 50 l of 6 M urea. Protein concentrations were determined using Fluka's Protein Assay Reagent with ␥-globulins (Sigma-Aldrich) as the standard. The amount of bound [ 14 C]CDDO was determined by liquid scintillation counting. This analysis was also performed with [ 14 C]CDDO added after the 1-h polymerization step. After an additional 30-min incubation (at 37°C), the assay was completed as described.
Screening for Covalent Binding of CDDO to Tubulin. Binding assays (55 l total volume) containing general tubulin buffer, 5 M tubulin, and 80 M [ 14 C]CDDO were incubated for 2 h at 37°C. Unbound [ 14 C]CDDO was removed using a MicroSpin G50 column. Ten microliters of eluate was combined with either SDS-PAGE loading buffer containing DTT (ϩDTT) or without DTT (ϪDTT). The samples were electrophoresed using a 4 to 12% SDS-PAGE gel (Invitrogen). Control samples, processed as outlined above but without the addition of [ 14 C]CDDO, were visualized by Coomassie staining. Gels with radiolabeled protein were placed in fixing solution [isopropanol/water/acetic acid (25:65:10)] for 30 min at 25°C, soaked in Amplify reagent (GE Healthcare) for 30 min (at 25°C), and then vacuum-dried (at 80°C) and visualized by autoradiography.
Binding of CDDO after Preincubation with DTNB. Tubulin (5 M) was combined with either 227 M 5,5Ј-dithio-bis-(2-nitrobenzoic acid) (DTNB; Sigma-Aldrich) or DMSO (control), incubated for 1 h at 37°C, and then passed through a MicroSpin G50 column to isolate the protein. Protein concentrations were determined as described, and 5 M was mixed with 55 M [ 14 C]CDDO and allowed to incubate for 1 h at 37°C. Unbound [ 14 C]CDDO was removed by gel filtration. Protein concentration and amount of bound radioligand were determined as described.
Results
Protein Targets of CDDO. To search for a protein target of CDDO, immobilized biotinylated CDDO was used to screen Ikeda et al., 2003) ]. The biotinylated CDDO construct (TP301; Fig. 1 ) was immobilized on streptavidin resin and used in affinity column chromatography. After extensive washing to disrupt nonspecific interactions, selective elution was performed with CDDO as the eluant. As seen in the silver-stained polyacrylamide gel shown in Fig. 2 , several abundant protein bands were obtained, as might be expected with a pleiotropic agent. Liquid chromatography-tandem mass spectrometry analysis of these protein bands identified the individual protein constituents, and based upon peptide occurrence and a rational evaluation of the identified proteins, tubulin was selected as a likely protein target of CDDO that could contribute to the initiation of the induction phase of apoptosis. The remaining proteins will be validated and discussed in subsequent communications.
A Secondary Screen. To confirm the specificity of the CDDO-tubulin interaction, a secondary screen was performed by evaluating the direct binding of CDDO to purified tubulin. Radiolabeled CDDO was incubated with either BSA or tubulin, and after unbound [
14 C]CDDO was removed by gel filtration, scintillation counting confirmed that CDDO selectively binds to tubulin (Fig. 3a) . Furthermore, a binding isotherm with [
14 C]CDDO and purified tubulin produced a dissociation constant of ϳ7 M (Fig. 3b) , which is comparable with the IC 50 value for CDDO-induced apoptosis of U937 cells (5 M). Thus, tubulin seemed to be a highly probable target of CDDO.
Indirect Immunofluorescent Microscopy. To evaluate whether CDDO would disrupt microtubules in vivo, osteosarcoma cells were treated with DMSO, CDDO, or nocodazole (a known spindle poison), and microtubules were examined at various time points by indirect immunofluorescent microscopy. The IC 50 value for CDDO-induced apoptosis of osteosarcoma cells is ϳ6 M (Ito et al., 2001 ). As expected, cells treated with DMSO (the solvent for nocodazole and CDDO) for either 1 h (Fig. 4a ) or 24 h (not shown) exhibit normal microtubules. In contrast, a 1-h treatment of cells with 10 M nocodazole results in the near complete depolymerization of microtubules (Fig. 4b) . Similar in appearance to DMSO- . CDDO interactions with tubulin and microtubules. a, the polymerization of 40 M tubulin (in 1 mM GTP, 1 mM MgCl 2 , 250 M EGTA, and 40 mM PIPES, pH 6.9) was monitored spectrophotometrically at 340 nm in the presence of various concentrations of CDDO (0 -100 M). Polymerization was initiated by elevating the temperature of the assay mixture from 4 -37°C, and the extent of polymerization was recorded at 4-min time intervals over the course of 1 h. A plot of percent tubulin polymerized (OD 340 at 60 min) versus the log of CDDO concentration was used to calculate an IC 50 value of 31 M. b, the dose-dependent depolymerization of microtubules by CDDO. After 60 min of tubulin polymerization, CDDO was added at the indicated concentrations. For clarity, the average polymerization (OD 340 value) is presented for the first 60 min of the assay. The average polymerization trace thereafter represents a control with 0 M CDDO added at 60 min. c, radiolabeled CDDO was added either before or after a tubulin polymerization reaction, and the amount of radioactivity associated with unincorporated tubulin or microtubules was determined.
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at ASPET Journals on June 29, 2017 molpharm.aspetjournals.org treated cells, the majority of cells treated for 1 h with 5 M CDDO seemed to have unaffected microtubules (Fig. 4c) . However, with prolonged incubation, microtubule depolymerization becomes apparent (Fig. 4, d and e) . At higher concentrations of CDDO, rapid microtubule disruption is observed (Fig. 4f) . Collectively, these results illustrate that CDDO does indeed influence microtubules in vivo, further supporting the possibility of tubulin as a target of CDDO. However, CDDO seems less potent than nocodazole, which may simply reflect the greater affinity of tubulin for nocodazole [K d ϭ 0.3-1.5 M (Tahir et al., 2000; Xu et al., 2002) ]. Alternatively, the relative potencies could be a consequence of the cellular permeability of each molecule (note that nocodazole is uncharged, whereas CDDO is anionic at physiological pH). Regardless, these results motivated further investigations to probe the nature of the CDDO-tubulin interaction.
The CDDO-Tubulin/Microtubule Interaction. Because CDDO caused the disruption of microtubules in vivo, we set out to evaluate its effects on microtubules in vitro. Cuvettes containing 4 mg/ml tubulin, 1 mM GTP, 1 mM MgCl 2 , 250 M EGTA, 40 mM PIPES, pH 6.9, and variable concentrations of CDDO (0-100 M) were placed into a spectrophotometer and the polymerization of tubulin was monitored at 340 nm. Polymerization was initiated by elevating the temperature of the assay mixture from 4-37°C, and the extent of polymerization was recorded at 4-min time intervals over the course of 1 h. The dose-dependent inhibition of tubulin polymerization by CDDO is illustrated in Fig. 5a . When assayed with 40 M tubulin, CDDO inhibits microtubule formation, with an IC 50 value of 30 M. To evaluate the relative efficacy of CDDO, the same assay was performed with the potent microtubule inhibitors colchicine (IC 50 ϭ 1.4 M), vinblastine (IC 50 ϭ 1.2 M), and bis-ANS (IC 50 ϭ 20 M) (data not shown). Not surprisingly, the relative efficacies seem directly proportional to the affinity of tubulin for each of these inhibitors: CDDO, Horowitz et al., 1984) ; colchicine, K d ϭ 0.3 to 1.4 M (Williams et al., 1983; Tahir et al., 2000) ; and vinblastine, K d ϭ 0.5 M (Safa et al., 1987) .
Because CDDO was observed to depolymerize microtubules in vivo, we also tested the effects of adding CDDO to preformed microtubules in vitro. As seen in Fig. 5b , CDDO is capable of depolymerizing microtubules in a dose-dependent fashion. This observation raised the possibility that CDDO might be capable of directly binding to microtubules. To explore this possibility, radiolabeled CDDO was added to tubulin polymerization reactions either before the reactions were initiated or after they were complete. Examination of [ 14 C]CDDO-bound soluble-tubulin (i.e., tubulin that is not incorporated into microtubules) illustrates little difference in binding whether CDDO was added before or after microtubules were formed (Fig. 5c) . On the other hand, examination of the protein polymer suggests that CDDO is indeed capable of directly binding to microtubules, and at elevated concentrations of CDDO, over 2-fold greater binding is observed when [
14 C]CDDO is added to preformed microtubules. In fact, with 55 M [ 14 C]CDDO, the molar ratio of CDDO to protein suggests that CDDO binds to multiple sites on tubulin in microtubules. Because tubulin hydrolyzes GTP to GDP when polymerized into microtubules, we tested the possibility of GTP hydrolysis influencing the binding of CDDO to tubulin. However, CDDO did not preferentially bind to either GTP-or GDP-tubulin (data not shown). Thus, although CDDO seems capable of binding to preformed microtubules and may do so at multiple sites on tubulin, the specific details of this binding remain unclear.
The CDDO Binding Site. To localize the CDDO binding site on the tubulin heterodimer, a competitive scintillation proximity assay was performed in the presence of vinblastine, colchicine, or bis-ANS. As seen in Fig. 6a , bis-ANS inhibits [
14 C]CDDO binding to tubulin. A double reciprocal plot of CDDO binding in the absence and presence of 50 M bis-ANS (Fig. 6b) indicates that bis-ANS is a competitive inhibitor of CDDO, implying that these two molecules share the same binding site. Because the bis-ANS binding site on tubulin is thought to be hydrophobic , the CDDO-tubulin interaction probably also involves hydrophobic interactions.
The Role of Sulfhydryls. The structure of CDDO contains two electrophilic ␣,␤-unsaturated carbonyl moieties, one in ring A and one in ring C (Fig. 1) , raising the possibility that the CDDO-tubulin interaction may involve a conjugate nucleophilic addition. We have recently reported that molecules containing sulfhydryl groups, such as DTT or glutathione, can form reversible adducts with CDDO through pref- Downloaded from erential addition to the ring A enone moiety (Couch et al., 2005) . Although the A-ring enone was found to be highly reactive toward nucleophilic additions, spectroscopic analysis revealed that the adducts were quite unstable and would quickly undergo elimination by ejection of the nucleophile. Specifically, NMR experiments intended to monitor the proton in ring A showed that simply elevating the temperature to 37°C caused the covalent thiol adduct to disintegrate. In addition, UV-visible spectroscopy experiments showed that the covalent adduct disintegrated over 30 min. In light of these observations, we first set out to evaluate if the CDDOtubulin interaction might involve a sulfhydryl group from tubulin. As shown in Fig. 7a , the binding of [
14 C]CDDO to DTNB-pretreated tubulin was significantly reduced relative to tubulin not pretreated with DTNB, supporting the possibility of the involvement of a sulfhydryl group in the CDDOtubulin interaction. Then, to investigate if the ring A enone contributes to this interaction, a competitive scintillation proximity assay was performed with CDDO and its reduced analog, dihydro-CDDO-methyl ester (Fig. 1) . As shown in Fig. 7b , the binding of dihydro-CDDO-methyl ester is reduced relative to that of CDDO (i.e., dihydro-CDDO-methyl ester is a poorer inhibitor of [ 14 C]CDDO binding than is CDDO), supporting the possibility that the ring A enone contributes to the CDDO-tubulin interaction. Together, the DTNB and dihydro-CDDO-methyl ester experiments imply the possibility of a conjugate addition between a sulfhydryl and the ring A enone. And finally, to determine whether the CDDO-tubulin interaction is irreversible (i.e., a nucleophilic addition results in a stable covalent bond), tubulin was incubated with [ 14 C]CDDO and then electrophoresed and visualized by autoradiography. As shown in Fig. 7c , radioactivity is not associated with protein electrophoresed in either the presence or absence of DTT (which could potentially disrupt the CDDO-tubulin adduct). Thus, it seems that CDDO interacts with a hydrophobic site on tubulin, and it may involve a 1,4-addition via a sulfhydryl group, but this interaction is probably reversible. Additional experiments will be necessary to further elucidate the details of the interaction.
CDDO and the Mitotic Index. Collectively, the aforementioned results clearly indicate an interaction between CDDO and tubulin and support the hypothesis that this interaction contributes to CDDO-induced apoptosis. Spindle poisons typically function by causing a cell cycle block at M phase, which eventually initiates apoptosis (Jordan and Wilson, 1998) . To evaluate whether CDDO behaves as a typical spindle poison, the effects of CDDO on the mitotic index was determined. As shown in Table 1 , whereas treatment with nocodazole results in the temporal accumulation of M phase osteosarcoma cells, the mitotic index of CDDO-treated cells is observed to decline over time. Interestingly, the number of apoptotic cells that appear in the CDDO-treated culture closely parallels the number of M phase cells observed in the nocodazole-treated sample. Thus, in contrast to a typical spindle poison, it seems that CDDO rapidly induces apoptosis in treated cells. Hence, the combination of CDDO binding to tubulin and to an additional protein target may collectively contribute to the mechanism of CDDO-induced apoptosis.
TABLE 1
The effects of CDDO on the mitotic index The mitotic index was determined at several time points after exposure of osteosarcoma cells to either DMSO, 10 M nocodazole, or 5 M CDDO. Typical of a spindle poison, nocodazole increases the mitotic index by blocking cell progression in mitosis. In contrast, CDDO seems to diminish the number of mitotic cells. 14 C]CDDO for 2 h at 37°C. Unbound radiolabeled CDDO was removed by gel filtration, and the purified protein was electrophoresed and examined by autoradiography. ϪDTT and ϩDTT specifies that the protein was electrophoresed in the absence or presence of DTT, respectively. The location of tubulin (as determined by Coomassie staining) and [
Discussion
The semisynthetic triterpenoid CDDO is pleiotropic. CDDO suppresses the de novo synthesis of the inflammatory enzymes iNOS and cyclooxygenase-2 in activated macrophages, and because these enzymes have been implicated as possible enhancers of carcinogenesis (Hussain et al., 2003) , CDDO has potential to be used as a chemopreventive agent. Furthermore, CDDO may also serve as a chemotherapeutic agent, because it has been shown to effectively induce differentiation of human myeloid leukemia cells (Suh et al., 1999) , inhibit the proliferation of various human tumor cell types (Suh et al., 1999; Lapillonne et al., 2003) , and induce apoptosis in several human cancer cell lines, including cell lines resistant to other chemotherapies. Affinity column chromatography, using immobilized CDDO and a human lymphoma cell line sensitive to CDDO-induced apoptosis, identified tubulin as a protein target (Fig. 2) . Competitive binding studies suggest that CDDO is likely to bind to ␤-tubulin using a combination of hydrophobic interactions and a reversible 1,4-addition with a protein sulfhydryl group (Figs. 6 and 7) . Thus, like many other sulfhydryl-binding compounds known to inhibit tubulin polymerization (Kuriyama and Sakai, 1974; Mellon and Rebhun, 1976; Deinum et al., 1981; Lee et al., 1981; Luduena and Roach, 1981; Roach and Luduena, 1984; Bai et al., 1989; Li and Broome, 1999; Shan et al., 1999; Combeau et al., 2000) , CDDO may function in part by disrupting the regulatory role of a sulfhydryl group in the formation of the mitotic spindle . Furthermore, because the binding site of CDDO on ␤-tubulin was localized to a region also bound by bis-ANS, which is thought to reside in a flexible area distal from the ␣␤-interface (Ward et al., 1994) , CDDO may also inhibit tubulin polymerization in a manner analogous to bis-ANS (Mazumdar et al., 1992) . Interestingly, three cysteine residues have been suggested to reside within the bis-ANS binding site on ␤-tubulin (Roychowdhury et al., 2000) . The fact that CDDO does not seem to arrest the cell cycle at M phase ( Table 1 ) could indicate that other protein targets of CDDO may be acting synergistically with tubulin to cause a rapid apoptotic event. Interestingly, this multitarget mode of action does not seem unique to CDDO, because the marine natural product stypoldione is thought to induce apoptosis by interacting with tubulin and other protein targets (O'Brien et al., 1983) . Multiple targets have also been implicated in the spindle poisons lupeol , estramustine (Speicher et al., 1994) , and quercetin (Gupta and Panda, 2002) .
